Geron just brought Timothy Williams on board as their new EVP and Chief Legal Officer - guy's got serious pharma credentials. Came from Vanda, before that AgNovos and Stryker, so he knows the commercial biotech playbook pretty well. Given that RYTELO's already approved and they're pushing into myelofibrosis trials, makes sense they'd want someone with his M&A and regulatory experience handling the legal side. The company secretary role's also part of the package, so he's basically their top legal gun now. Their CEO's talking about building a sustainable hematology company - sounds like they're gearing up for the long game beyond just the MDS indication. Interesting move considering where they are in the product cycle.